Targeted agents: the rules of combination.
The success of molecularly targeted agents (MTA) in the treatment of cancer has led to the investigation of their use in combination with other MTAs and with conventional chemotherapies. An overview of the MTAs that have emerged as Food and Drug Administration-approved drugs is presented, along with a framework for the consideration of how MTAs can best be combined to maximize therapeutic effect.
Kwak
Eunice L
EL
Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA. ekwak@partners.org
Clark
Jeffrey W
JW
Chabner
Bruce
B
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology / Q000627:therapeutic use*; D017277:Drug Approval; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents